Advances in surgical oncology have improved patient safety and provided less-invasive procedures. In the era of personalized medicine, the value of surgical specimens for understanding tumour biology, extended indication of surgery, the role of surgical oncology in trials that examine neoadjuvant therapy in patients selected by appropriate biomarkers, and the possibilities to personalize the surgical procedure itself according to lung cancer subtypes are discussed.
- Tetsuya Mitsudomi
- Kenichi Suda
- Yasushi Yatabe
